Christian Rolfo, MD, PhD, MBA, The Tisch Cancer Institute at Mount Sinai, New York, NY, provides an overview of strategies to increase widespread use of liquid biopsies in lung cancer. Compared to monitoring metastatic disease and minimal residual disease (MRD), early detection is relatively underdeveloped due to incomplete data. Higher sensitivity needs to be achieved for successful screening, especially in areas of the world with low screening capabilities. This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.